Buprenorphine is now increasingly prescribed as an alternative to methadone for the treatment of heroin addiction. Because of its potency (dosage usages from 0.2 mg to 8 rag), the drug concentrations in body fluids are normally very low. Here, we report the first recombinant glucose-6-phosphate dehydrogenase (G6PDH)-based homogeneous immunoassay (EMIT-type assay) for free buprenorphine and free norbuprenorphine in urine. The antibody used in this assay cross-reacts nearly identically with buprenorphine and norbuprenorphine and, at the same time, has less than 1% cross-reactivity with a wide range of commonly prescribed opiates, particularly those structurally related compounds such as morphine, codeine, and dihydrocodeine. More importantly, this assay has a low detection limit of I ng/mL for buprenorphine or norbuprenorphine. Further evaluation of this technique using gas chromatography-mass spectrometry (GC-MS) of authentic urine samples demonstrated that the accuracy of the assay is greater than 95 %. Because this assay is designed to measure the free drugs in urine, it resulted in simplification for GC-MS or liquid chromatography-MS confirmation methods that did not require urine hydrolysis before solid-phase or liquid-liquid extraction.
Introduction
Buprenorphine is a semisynthetic organic compound with a chemical structure similar to morphine (Figure 1 ). Currently, this drug is used as a substitution drug for opioid addiction and treatment of moderate to severe pain. Unlike morphine, buprenorphine possesses two strong hydrophobic side groups, which result in high lipid solubility and low therapeutic concentrations (1-3).
Buprenorphine is 20--40 times more potent than morphine and has contributed to several fatalities (4) , which may be ascribed to permissive prescription on a large scale and availability on the black market.
In the past 25 years, extensive studies on the properties and clinical applications of buprenorphine including pharmacokinetics, pharmacodynamics, administration, and maintenance treatment have resulted in hundreds of publications. However, little effort has been paid to the development of immunoassay methods suitable for high-volume screening for norbuprenorphine in biological samples (5) . Because of the very low therapeutic concentrations, administration and monitoring of buprenorphine still presents a great challenge in clinical and forensic laboratories.
A wide range of lab-based separation techniques and confirmation methods such as high-performance liquid chromatography-ultraviolet detection (HPLC-UV), gas chromatographymass spectrometry (GC-MS), and liquid chromatography (LC)-MS-MS for the detection of buprenorphine in plasma, urine, hair, and sweat (6-10) have been reported. However, these techniques normally employ tedious procedures or sophisticated instruments that are not suitable for the identification of buprenorphine in a large-scale environment. Immunoassay methods often offer rapid and sensitive detection of the target molecules in various matrices. Several heterogeneous immunoassays such as microplate ELISA (11) (12) (13) (14) , rapid strip testing (15) , and radioimmunoassay (16) have been applied to detect buprenorphine in blood, urine, and hair. In addition, faster and more efficient homogeneous immunoassays such as fluoroimmunoassay (17) , CEDIA-type assay (18) , and EMIT-type assay (19, 20) for buprenorphine and its metabolites in body fluids have also been reported. However, most of the existing immunoassays are based on the anti-buprenorphine antibodies that could be raised through the phenolic group on buprenorphine because the parent drug buprenorphine-based antigens are easily prepared and commercially available. More importantly, this phenolic point is common to many structurally related opiates and their major metabolites. As a result, antibodies could have some undesired cross-reactivity with certain opiates, which could explain why a high percentage of false-positive results was observed in some studies (13, 18) .
The goal of this study was to develop an alternative rapid buprenorphine homogeneous screening method to overcome these drawbacks. Ideally, the antibody should have equal crossreactivity with buprenorphine and norbuprenorphine because the concentrations of norbuprenorphine in urine are generally higher than buprenorphine (median = 5). Therefore, it is highly desirable to develop an immunoassay with high crossreactivity with its major metabolite norbuprenorphine.
In this paper, an improved homogeneous immunoassay for specific, sensitive, and rapid detection of both buprenorphine and norbuprenorphine in urine is described. This newly developed method has a low detection limit of 1 ng/mL and shows greater than 95% correlation with GC-MS. As a result, a semiquantitative assay with a working range between 0 and 40 ng/mL can be developed accordingly.
Materials and Methods

Urine samples
Among the 76 urine samples, 15 urine specimens were obtained from Ms. Eleanor Miller's laboratory (University of Glasgow, Scotland), 33 urine positive specimens were provided by Alpha Scientific Design, and 23 negative urine samples were collected from non-buprenorphine users.
Chemicals and reagents
Mono and dibasic sodium phosphates, Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl), sodium chloride, hydrochloric acid, and sodium hydroxide were purchased from Spectrum Chemicals (Gardena, CA). Deuterated buprenorphine-d4 and norbuprenorephine-d3 as well as the unlabelled drug standards were obtained from Cerilliant (Round Rock, TX). Solid-phase extraction (SPE) columns (Part #691-0353T) were purchased from SPE Ware (San Pedro, CA). The derivatizing reagent N,O-bis (trimethylsilyl) trifluoroacetamide + 1% trimethylchlorosilane (BSTFA + 1% TMCS) was obtained from Pierce (Rockford, IL). Ammonium hydroxide was obtained from Aldrich (Milwaukee, WI). All solvents used were HPLC grade and all chemicals were ACS grade. For GC-MS and immunoassay, the controls and calibrators of buprenorphine and norbuprenorphine were prepared in synthetic urine [0.1M phosphate buffered saline (PBS), 0.1% bovine serum albumin (BSA) adjusted to pH 7.0] and stored at 4~ For GC-MS, working solutions of calibrators at 1000 ng/mL in methanol and internal standard at 5000 ng/mL in methanol were prepared and stored at -20~ The recombinant glucose-6-phosphate dehydrogenase (G6PDH) was provided by Dade Behring.
Extraction procedure
Urine (1 mL) was removed and deuterated internal standard (20 pL, 1000 ng/mL) was added to the calibrators and controis. A calibration curve at concentrations of 0, 0.5, 1, 2, 5, 10, and 50 ng/mL was prepared and analyzed with each batch.
One milliliter of potassium phosphate buffer (0.1M, pH 6.0) was added to the samples and mixed. Solid-phase extraction columns were placed on top of the vacuum manifold and conditioned with methanol (2 mL) and 0.1M potassium phosphate buffer (pH 6, 2 mL). The sorbent bed was not allowed to dry. Each sample was poured through the extraction column, then each column was rinsed with deionized water (2 mL), 1raM acetate buffer (pH 4.0, 2 mL), methanol (2 mL), and ethyl acetate (1 mL). The columns were dried for 2 min. Finally, the drugs were eluted with ethyl acetate/ammonium hydroxide (98:2, 2 mL) and the eluents evaporated to dryness under a gentle stream of nitrogen.
The dried extracts were reconstituted in ethyl acetate (20 pL) and BSTFA (with 1% TMCS, 20 pL), capped, and mixed. The samples were transferred to autosampler vials, capped, and heated at 70~ for 20 rain.
GC-MS analytical method
An Agilent 6890N GC coupled to a 5975 mass selective detector (MSD) with an inert source, operating in electron impact mode was used for analysis. The GC column was a DB-5MS (15-m length, 0.25-ram i.d., 0.25-mm film thickness, J&W Scientific), and the injection temperature was 250~ The purge flow rate was 50 mL/min for I rain, and the carrier gas was helium. The injection mode was splitless, injection volume was 2 mL, and the operation mode was constant flow at 1.5 mL/min. The initial oven temperature was 180~ where it was held for 0.5 rain, then ramped at 30~ to 300~ The transfer line was held at 280~ the ion source at 230~ and the quadrupole at 150~ The dwell time for all ions was 50 ms.
Buprenorphine-d4 was found at a retention time of 6.82 rain, and the ions selected were m/z 454.3 and 486.3. Buprenorphine was found at a retention time of 6.85 min and two ions were selected from the full scan spectrum, m/z 450,3, 506.3. Norbuprenorphine-d3 and norbuprenorphine were detected at retention times of 5.8 and 5.82 min, respectively. The ions for the deuterated internal standard were 503.3 and 527.3; for unlabelled norbuprenorphine, the ions were 500.3 and 557.0. The quantifying ions are underlined. Each analysis required the ion ratio between the quantifier ion and the qualifier ion to be within • 20% in order to meet the criterion for a positive result.
Immunoassay protocol
The homogeneous immunoassays were performed on a Hitachi 717 with the following protocol: 20 pL sample (controls) and 110 pL of antibody solution (RA) were added and incubated for 5 rain, and enzyme conjugate solutions (RE, 60 pL) were added. The enzyme rate (change in absorbance at 340 nm) was measured every 6 s, and the data were obtained between 120 and 180 s.
Preparation of RA and RE
To our knowledge, we are the first to be able to raise an anti-buprenorphine polyclonal antibody with almost 100% cross-reactivity for both buprenorphine and norbuprenorphine (11, 12) . In our ongoing efforts to improve the homogeneous immunoassay performance for buprenorphine, a series of buprenorphine-enzyme conjugates were prepared and tested. One of the G6PDH-buprenorphine conjugate afforded the most desirable performance. These buprenorphine-enzyme conjugates were diluted with 0.1M Tris-HCl buffer (pH 7.8), which contains 0.1% BSA and 0.05M G6P. The anti-buprenorphine antibody that was raised in-house was diluted with 20raM Tris-Cl buffer (pH 6.0) containing 0.05M NAD and 0.5% NaCI. Calibrators and controls were made by adding buprenorphine to synthetic urine.
Results and Discussion
Evaluation of binding activities of antibody and enzyme conjugate
When the buprenorphine-G6PDH conjugate was mixed with excess anti-buprenorphine antibody, about 50% inhibition of enzyme activity resulted. This inhibition can be reversed by addition of excess amount (> 1000 ng/mL) of buprenorphine or norbuprenorphine. The enzyme activity is directly proportional to the concentrations of free drugs in solution. Standard curves were generated based on calibrators of 0, 5, 10, 20, and 40 ng/mL (Figure 2) .
Sensitivity
Based on the minimum buprenorphine concentration required to produce a two standard deviations from the negative calibrator, the detection limit for buprenorphine or norbupreborphine was determined to be 1 ng/mL, therefore the cutoff concentration could conservatively be set at 5 ng/mL. More significantly, it was possible to perform a semiquantitative assay at 5 ng/mL as the reaction rate exhibited distinct difference between 3.75, 5, and 6.75 ng/mL (Table I) .
Identical cross-reactivity between buprenorphine and norbuprenorphine
Both buprepnorphine and norbuprenorphine were added to synthetic urine and the pooled human urine at concentrations ranging from 2.5 ng/mL to 40 ng/mL. No matrix ef- fect was observed as the pooled human urine specimens yielded almost the same background as synthetic urine. Since buprenorphine and norbuprenorphine exhibit virtually identical immunochemical reactivity ( Figure 3 ) this unique assay has almost 100% cross-reactivity for both buprenorphine and norbuprenorphine, which makes it quite different from commercially available buprenorphine homogeneous immunoassays which have very low crossreactivity with norbuprenorphine.
In addition, we also observed excellent recovery yields (> 95%) for both buprenorphine and norbuprenorphine with concentrations ranging from 2.5 to 40 ng/mL because the freshly spiked calibrators and the control calibrators afforded almost identical dose-response curves.
Precision
The negative, 5, 10, 10, 20, and 40 ng/mL controls were assayed using a Hitachi 717 analyzer (n = 10, Table II ). The precision of the assay was less than 1% CV within-run (n = 10), and less than 3% CV between-runs (5 days, n = 50).
Specificity
A wide range of commonly prescribed opiates with chemical structures closely related to buprenorphine was tested at 10,000 ng/mL. The results are shown in Table Ill . None of them, specifically morphine, codeine, and dihydrocodeine, showed positive results when 5 ng/mL of buprenorphine was used as the cutoff concentration.
Interference with unrelated drugs
Other commonly used drugs that are structurally unrelated to buprenorphine were also assayed. Aliquots of a human urine matrix were spiked with the following compounds at a concentration of 10,000 ng/mL. None of these compounds gave values in the assay that were equal to or greater than the assay sensitivity level (1.25 ng/mL) as shown in Table IV . 
Accuracy
A total of 39 human urine specimens were assayed using the G6PDH-based homogeneous immunoassay method. Among 39 urine samples, 15 clinical urine samples were obtained from Ms. Eleanor Miller's laboratory (University of Glasgow, Scotland) with total buprenophine concentration ranging from 0 to 2000 ng/mL and norbuprenorphine con- centrations ranging from 0 to 6000 ng/mL confirmed by LC-MS-MS (11) . The rest of the 24 negative urine samples were collected from non-buprenorphine users. The sensitivity and specificity were all 100% (Table V) . After re-analyzing the free drug concentrations in the previously LC-MS-MS confirmed positive urine specimens (11) , all the positive urines contained significant amounts of free norbuprenorphine (3 to 500 ng/mL) and buprenorphine (0.5 to 87 ng/mL) (Table VI) . These results revealed that free drugs are present in urine specimens. The ratios of free norbuprenorphine to buprenorphine ranged between 5 and 66.
To further evaluate the assay performance of the recombinant G6PDH based homogeneous immunoassay, 33 clinical urine samples with free drug concentrations around 5 to 10 ng/mL were obtained from Alpha Scientific Design (San Diego, CA). Table VII summarizes the data, and only one sample was assayed as negative, further confirming that the newly developed recombinant G6PDH-based immunoassay method is sensitive enough to be used in field applications using 5 ng/mL as cutoff concentration.
Conclusions
A highly sensitive and rapid immunoassay screening method to detect norbuprenorphine and buprenorphine in urine has been developed and further validated with GC-MS-or LC-MS-MSverified urine samples. This recombinant G6PDH-based homogeneous immunoassay is reliable with accuracy greater than 95%. More importantly, this assay employed an antibody that binds specifically and almost equally to free buprenorphine and norbuprenorphine. In addition, we also analyzed the free drugs in authentic urine samples using GC-MS and found that the mean ratio of free norbuprenorphine to free buprenorphine is approximately 35. The combined concentrations of the free drugs are above 5 ng/mL were used as cutoff concentration for positive urine samples. A wide range of commonly prescribed opiates was also assayed at high concentration and none produced positive results. This proves that this buprenorphine homogeneous immunoassay is very specific with very low cross-reactivity to structurally related opiates, particularly morphine, codeine, and dihydrocodeine.
